AI tools are frequently used in data visualization — this article describes how they can make data preparation more efficient ...

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy ...

Every clinical setback carries lessons. That’s why Fierce revisits major trial failures each year: not to dwell on disappointment, but to understand what went wrong and what it signals for the road ...

Investing.com - Raymond James upgraded Vir Biotechnology (NASDAQ:VIR) to Strong Buy from Outperform and raised its price target to $19.00 from $12.00. The stock, currently trading at $7.43, has surged ...

Investing.com -- Edesa Biotech Inc (NASDAQ:EDSA) shares surged 77% Tuesday after the company reported positive additional data from a Phase 3 study of paridiprubart, showing statistically significant ...

Vir Biotechnology will receive $335 million in upfront and near-term milestone payments, including $240 million in cash and $75 million in equity investment at a 50% premium. Additionally, Vir is ...

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value ...

Investing.com - Shares of Grail shed nearly 47% of their value in premarket U.S. trading Friday, after the biotech firm’s flagship NHS-Galleri trial failed to meet its primary clinical endpoint of a ...

Indexes down: Dow 1.34%, S&P 500 1.57%, Nasdaq 2.04% Weekly jobless claims fell less than expected last week Tech, megacaps, transport stocks sell off sharply Personal computer makers dip after peer ...

Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be ...

Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms,with an impressive history of delivering significant ...